Pharmacoeconomic Analysis of the Use of Omeprazole by Elderly Patients in One of the Primary Healthcare Centers in Brazil
DOI:
https://doi.org/10.15343/0104-7809.202347e1452020PKeywords:
Elderly, Omeprazole, Prescription, Medication Errors, PharmacoeconomicsAbstract
Omeprazole is the most prescribed proton pump inhibitor in Brazil and is indicated for the treatment of diseases caused by gastroesophageal reflux, peptic ulcer, erosive esophagitis, eradication of Helicobacter pylori, Zollinger-Ellison syndrome, gastrinomas, gastritis, and hypersecretory disorders, as well as peptic ulcer prevention. The indiscriminate and unnecessary use, mainly by the elderly, is an important public health issue to be addressed. Despite the existence of indiscriminate use of omeprazole being known, there is a need to verify how this medication is prescribed in the context of the Unified Health System (UHS) in Brazil. In addition, it is believed that studies that aim to analyze the prescription of omeprazole in a pharmacoeconomic way can contribute to the review or implementation of guidelines and protocols involving the use of this drug. The objective of this study was to characterize and perform a pharmacoeconomic analysis of the use of omeprazole in a Primary Healthcare Centers (PHC) in Minas Gerais, Brazil. This is a descriptive study analyzing the prescriptions of 41 elderly patients treated in the period of April/May 2018 and the following variables were identified: age, sex, dose, indication, endoscopy, other medications in use, and cost of treatment. In the pharmacoeconomic analysis, the average cost of the amount of omeprazole prescribed per patient was calculated and whether or not endoscopy was performed was considered. In the studied population, 29 (70.3%) were female with a median age: 69 years. Only in 4 medical records (9.8%) was there indication for use, and 18 (43.9%) patients had been using omeprazole for more than two years and 7 (17.1%) for more than five years. Only 3 (7.3%) patients underwent endoscopy, and 371 months-worth of omeprazole were used, totaling a financial value of R$35,657.23. The findings suggest long-term prescriptions and no record of their indication on medical records. The cost related to prescriptions could be optimized by performing endoscopy and discontinuing its use when no indication is found.
Downloads
References
2. Simões CCS. Relações entre alterações históricas na dinâmica demográfica brasileira e os impactos decorrentes do processo de envelhecimento da população. Rio de Janeiro: IBGE; Coordenação de População e Indicadores Sociais. 2016. Disponível em: https:// biblioteca.ibge.gov.br/visualizacao/livros/liv98579.pdf .
3. Veras R. Population aging today: demands, challenges and innovations. Rev Saude Publica. 2009 maio;25(3):548-554. doi: 10.1590/ S0034-89102009005000025.
4. Brito MC, Freitas CA, Mesquita KO, Lima GK. Envelhecimento Populacional e os Desafios para a Saúde Pública: Análise da Produção Científica. Rev Kairos. 2013;16(2):161-178. doi: 10.23925/2176-901X.2013v16i2p161-178.
5. Kernkamp CL, Costa CK, Massuda EM, Silva ES, Yamaguchi UM, Bernuci MP. Perfil de morbidade e gastos hospitalares com idosos no Paraná, Brasil, entre 2008 e 2012. Cad Saude Publica. 2016;32(7). doi: 10.1590/0102-311X00044115.
6. Marin MJS, Rodrigues LCR, Druzian, S, Cecílio LCO. Diagnósticos de enfermagem de idosos que utilizam múltiplos medicamentos.
Rev Esc Enferm USP. 2010;44(1):47-52. doi: 10.1590/S0080-62342010000100007.
7. Braga MP, Silva CB, Adams AI. Inibidores da bomba de prótons: revisão e análise farmacoeconômica. Saúde (Santa Maria, Rio Grande do Sul, Brazil). 2011;37(2):19-32. doi: 10.5902/223658342963.
8. Oliveira MG, Amorim WW, Oliveira CR, Coqueiro HL, Gusmão LC, Passos LC. Consenso brasileiro de medicamentos potencialmente inapropriados para idosos. Geriatr Gerontol Aging. 2016;10(4):168-181. doi: 10.5327/Z2447-211520161600054.
9. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. JAMA. 2006;296(24):2947- 2953. doi: 10.1001/jama.296.24.2947.
10. Pimenta LR, Soares RS, Castro PF, Freitas JG, Nielson SE. Uso indiscriminado de omeprazol em idosos e a importância da atenção farmacêutica. Rev Universo. 2016;1(3):303-318. Disponível em: http://revista.universo.edu.br/index. php?journal=3GOIANIA4&page=article&op=view&path%5B%5D=3113.
11. Freedberg DE, Kim LS, Yang YX. The risk and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from The American Gastroenterological Association. Gastroenterology. 2017;154(4):706-715. doi:10.1053/j.gastro.2017.01.031
12. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection. Arch Intern Med. 2010;170(9):772-778. doi: 10.1001/archinternmed.2010.73
13. Yanagihara GR, Paiva AG, Pacheco Neto M, Torres LH, Shimano AC, Louzada MJQ, Annoni R, Penoni ACO. Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso. Rev Bras Ortop (Sao Paulo). 2015;50(2):232–238. doi: 10.1016/j.rbo.2014.05.012
14. Morschel CF, Mafra D, Eduardo JCC. Inibidores da bomba de prótons e sua relação com a doença renal. J Bras Nefrol. 2018;40(3):301- 306. doi: 10.1590/2175-8239-jbn-2018-0021.
15. Kuller LH. Do proton pump Inhibitors Increase the risk of dementia? JAMA neurol. 2016;73(4):379-381. doi: 10.1001/ jamaneurol.2015.4931
16. Filho JPPM, Hashimoto CL. II Consenso Brasileiro da Doença do Refluxo Gastroesofágico. Departamento de Gastroenterologia da Faculdade de Medicina da Universidade de São Paulo. 2003: 43-59. Disponível em: http://universidadefbg.com.br/arq/consensos/ u3_r1.pdf
17. Forgacs I, Fox M. Clinical review: Gastrooesophageal reflux disease. BMJ 2006; 332:88-93. doi: 10.1136/bmj.332.7533.88
18. Moraes EM, Reis AMM, Moraes FL. Manual de terapêutica segura no idoso. Belo Horizonte: Folium, 2019:362-365. Disponível em: https://www.ivcf20.com.br/produto/78/MANUAL-DE-TERAPEUTICA-SEGURA-NO-IDOSO.
19. Lima APV, Neto Filho MA. Efeitos em longo prazo de inibidores bomba de prótons. Braz J Surg Clin Res. 2014;5(3):45-49. Disponível em: https://www.mastereditora.com.br/periodico/20140301_1352032.pdf
20. ANVISA (Agência Nacional de Vigilância Sanitária). Índice ATC. Disponível em: http://www.anvisa.gov.br/datavisa/Substancia/ ATC.htm. Organização Mundial de Saúde (OMS). Índice ATC / DDD 2020. [Acessado 2018 ago 25]. Disponível em: https://www. whocc.no/atc_ddd_index
21. Psendziuk C, Nuñez MR, Nicoleit AR, Rodrigues DF, Pereira SW, Galvani GC. Prevalência de sintomas de doença do refluxo gastroesofágico em pacientes com indicação de endoscopia digestiva alta. ACM. Arquivos catarinenses de medicina. 2010;39(1):62- 69. doi: http://www.acm.org.br/acm/revista/pdf/artigos/787.pdf
22. ANVISA (Agência Nacional de Vigilância Sanitária). Agência Nacional de Vigilância Sanitária (ANVISA). Listas de preços de medicamentos. [Acessado 2018 ago 25]. Disponível em: http://portal.anvisa.gov.br/cmed.
23. Vasconcellos MM, Gribel EB, Moraes IHS. Registros em saúde: avaliação da qualidade do prontuário do paciente na atenção básica. Cad Saude Publica. 2008;24(1):173-182. doi: 10.1590/S0102-311X2008001300021.
24. BCB (Banco Central do Brasil). Cotação do dólar. [Acessado 2021 mar 07]. Disponível em: https://www.bcb.gov.br/ estabilidadefinanceira/historicocotacoes.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 CCBY Creative Commons
This work is licensed under a Creative Commons Attribution 4.0 International License.
